Application

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

---

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Trademark/Service Mark Application, Principal Register

Serial Number: 97635376

Filing Date: 10/17/2022

To the Commissioner for Trademarks:

MARK: CRISPR THERAPEUTICS DE&I IT'S IN OUR DNA DIVERSITY, EQUITY, AND INCLUSION (Standard Characters, see mark)
The literal element of the mark consists of CRISPR THERAPEUTICS DE&I IT'S IN OUR DNA DIVERSITY, EQUITY, AND INCLUSION. The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, CRISPR Therapeutics AG, a aktiengesellschaft legally organized under the laws of Switzerland, having an address of
      Baarerstrasse 14
      ZUG V8 SWITZERLAND 6300
      Switzerland
      XXXX

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

International Class 041:  Education services, namely, providing on-line non-downloadable articles and newsletters in the field of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy.
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.

International Class 042:  Scientific research and development, namely, gene editing for researching and developing human cells and pharmaceuticals; research and development of therapeutics pharmaceuticals using gene editing; pharmaceutical, medical, scientific, and biopharmaceutical research and development; medical laboratory services; scientific laboratory services; custom cell-line engineering services; medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; providing medical research and scientific research information in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; scientific research and development services relating to targeting genetic therapies to individuals.
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.


Claim of Active Prior Registration(s)
The applicant claims ownership of active prior U.S. Registration Number(s) 6724517, 5916960, 5916961, and others.


The owner's/holder's proposed attorney information: Tiffany D. Gehrke. Tiffany D. Gehrke of Marshall, Gerstein & Borun LLP, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, is located at
      6300 Willis Tower
      233 South Wacker Drive
      Chicago, Illinois 60606
      United States
      312-474-6300(phone)
      docket@marshallip.com
The docket/reference number is 33324/60055.
Tiffany D. Gehrke submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant's current Correspondence Information:

Tiffany D. Gehrke

PRIMARY EMAIL FOR CORRESPONDENCE: docket@marshallip.com        SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): kkleinwachter@marshallip.com; tgehrke@marshallip.com Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).

A fee payment in the amount of $700 has been submitted with the application, representing payment for 2 class(es).

Declaration

	Basis: If the applicant is filing the application based on use in commerce under 15 U.S.C. § 1051(a): The signatory believes that the applicant is the owner of the trademark/service mark sought to be registered; The mark is in use in commerce and was in use in commerce as of the filing date of the application on or in connection with the goods/services in the application; The specimen(s) shows the mark as used on or in connection with the goods/services in the application and was used on or in connection with the goods/services in the application as of the application filing date; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate. And/Or If the applicant is filing the application based on an intent to use the mark in commerce under 15 U.S.C. § 1051(b), § 1126(d), and/or § 1126(e): The signatory believes that the applicant is entitled to use the mark in commerce; The applicant has a bona fide intention to use the mark in commerce and had a bona fide intention to use the mark in commerce as of the application filing date on or in connection with the goods/services in the application; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate.
	To the best of the signatory's knowledge and belief, no other persons, except, if applicable, concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services of such other persons, to cause confusion or mistake, or to deceive.
	To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the allegations and other factual contentions made above have evidentiary support.
	The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true.

Declaration Signature

Signature: /Anders Kassow/   Date: 10/17/2022
Signatory's Name: Anders Kassow
Signatory's Position: Executive Director, Intellectual Property
Signatory's Phone Number: Not Provided
Signature method: Sent to third party for signature
Payment Sale Number: 97635376
Payment Accounting Date: 10/17/2022

Serial Number: 97635376
Internet Transmission Date: Mon Oct 17 17:38:28 ET 2022
TEAS Stamp: USPTO/BAS-XX.XXX.XX.XXX-2022101717382963
3798-97635376-820a344e57824f1ac2cafc5e9b
98c44ca943dbfc79fca635ae0524e2a140be59-C
C-38282009-20221014154418978709